Report cover image

Clostridioides difficile Infections (CDI): Market View

Publisher GlobalData
Published Aug 20, 2025
Length 86 Pages
SKU # GBDT20389298

Description

Clostridioides difficile Infections (CDI): Market View

Summary

This reports provides a data-driven overview of the current and future competitive landscape in CDI Therapeutics.

In 2024, there were more than 2.04 million diagnosed incident cases of CDI in the 16 countries covered in GlobalData’s epidemiology forecast.

The current CDI market is dominated by several companies marketing genericized antibiotic therapies.

The CDI pipeline holds 48 molecules, with five molecule present in Phase III development.

Over the past 10 years, commercial sponsors headed trials for CDI, led by Pfizer (seven trials).

Over the past decade, partnerships have accounted for a significant portion of transactions in North America, representing 28.6% of the total deals. In contrast, Europe has seen acquisitions dominate, making up 40% of the deals.

Scope

GlobalData’s CDI: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the CDI Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global CDI Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

86 Pages
  • Report Scope
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Incident Cases of CDI in 2024 and 2029
    • Treatment Algorithm for CDI
    • Marketed Drugs - Leading Marketed Drugs in CDI
    • Marketed Drugs - Overview of Drugs by Approval and Drug Type
    • Marketed Drugs - Overview by MOA
    • Marketed Drugs - Overview by Molecule type
    • Marketed Drug Profile - Merck & Co.' s Zinplava
    • Marketed Drug Profile - Nestle's Vowst
    • Marketed Drug Profile - Rebiotix's Rebyota
    • Marketed Drug Profile - Merck & Co.' s Dificid
    • Marketed Drug Profile - COST-BRY's Biomictra
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Zinplava
    • Marketed Drugs - Time to Pricing for Rebyota & Vowst
    • Pipeline Drugs Overview - Early- to Late-Stage Pipeline Drugs in CDI
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by MOA
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by molecule type
    • Pipeline Drug Profile - Pfizer's PF-06425090 - Sales Forecast
    • Pipeline Drug Profile - Pfizer's PF-06425090 - Summary
    • Pipeline Drug Profile - Lumen Bioscience's LMN-201 - Sales Forecast
    • Pipeline Drug Profile - Lumen Bioscience's LMN-201- Summary
    • Pipeline Drug Profile - Vedanta Biosciences' VE-303 - Sales Forecast
    • Pipeline Drug Profile - Vedanta Biosciences' VE-303 - Summary
    • Pipeline Drug Profile - Mikrobiomik Healthcare's MBK-001
    • Pipeline Drug Profile - TenNor Therapeutics' rifasutenizol - Sales Forecast
    • Pipeline Drugs - PTSR and LoA in Infectious Disease & CDI
    • Pipeline Drugs - PTSR and LoA in CDI
    • Clinical Trials in CDI - Historical Overview by Phase
    • Clinical Trials in CDI - Historical Overview by Sponsor Type
    • Clinical Trials in CDI - Overview by Phase
    • Clinical Trials in CDI - Overview by Status
    • Clinical Trials in CDI - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in CDI - Trials with a Virtual Component
    • Clinical Trials in CDI - Top 20 Biomarkers by Trial Phase
    • Clinical Trials in CDI - Geographic Overview
    • Clinical Trials in CDI - Single-Country and Multinational Trials by Region
    • Clinical Trials in CDI - Top Sponsors with Breakdown by Phase
    • Clinical Trials in CDI - Top Sponsors with Breakdown by Status
    • Clinical Trials in CDI - Overview by Endpoint Status
    • Clinical Trials in CDI - Overview by Race and Ethnicity of Trial Participants
    • Clinical Trials in CDI - Enrollment Data
    • Clinical Trials in CDI - Overview of Sites by Geography
    • Clinical Trials in CDI - Top 20 Countries for Trial Sites
    • Clinical Trials in CDI - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for CDI
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in CDI by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in CDI
    • Commercial Assessment - Key Market Players in CDI
    • Future Market Catalysts - Upcoming Market Catalysts in CDI
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us